In August 2021, Lauren Breslin, a now 30-year-old landscape development manager from Robinson, was told she likely had ductal carcinoma in situ, also known as Stage 0 breast cancer.

She remembered her grandmother crying, “I just can't believe you have to go through this.” Her grandmother, now 88, had lost both her breasts and 12 lymph nodes when she was given a breast cancer diagnosis decades ago, at age 42.

If breast cancer spreads, it typically goes first to a few nearby lymph nodes under the arm, known as sentinel nodes. Surgeons used to remove them routinely as a precaution. But for many patients, the loss of lymph nodes brings a host of chronic side effects, said Suzanne Coopey, a breast surgeon who directs breast surgery for the Allegheny Health Network.

Thanks to magnetic sensing technology, Breslin was able to keep her lymph nodes, eliminating the risk of lymphedema, a possible effect of lymph node removal.

Advertise with us

Lymph node removal can contribute to loss of arm function and the need for physical therapy after mastectomy. Though most patients regain full range of motion in their shoulders, Coopey noted that some patients “can get cording or axillary webbing where it does get really tight and hard to get full range of motion.” Stretching the arm above shoulder level can induce sharp pain.

In patients with lymphedema, the body cannot efficiently drain fluid from tissue in the arm. “They have to wear a compression sleeve all the time,” Coopey said. “They have to have a compression pump at their house to help manage the fluid that builds up in their arm.”

Breslin was aware of the risk because of her family history. After testing positive for a breast cancer gene mutation, her mother, Janet Breslin, underwent a prophylactic double mastectomy without the need for lymph node removal. Breslin also tested positive and planned to have the same procedure as her mother. But after her first mammogram, the doctors told her she had cancer, which could have spread to her lymph nodes.

She worried doctors would say something like, “We got all your cancer, but now you have to worry about lymphedema for the rest of your life.”

But in fall 2021, Allegheny Health Network rolled out the magnetic sensing technology Magtrace to embrace a new procedure called delayed sentinel lymph node biopsy. Approved by the Food and Drug Administration in 2018, the technology buys surgeons and patients time when conducting a mastectomy. They now have up to 30 days to remove lymph nodes suspected of harboring cancerous cells, sparing patients with ductal carcinoma in situ, or DCIS, from risk of unnecessary pain, infection and swelling.

Advertise with us

Of the 1.7 million new cases of breast cancer diagnosed globally each year, roughly 20% are DCIS, in which cancerous cells are found in the milk ducts of the breast but have not invaded the blood stream or lymphatic system. Removing the tumor itself successfully treats many patients, but others have to lose one or both breasts entirely depending on the extent of their cancer.

“It was automatic that these lymph nodes would be removed, just in case there was invasive cancer found,” Coopey said.

But only about 15% of mastectomies for DCIS turn out to be invasive cases requiring the lymph node biopsy, she said.

For the 85% of mastectomy patients like Breslin whose cancer is truly non-invasive, Magtrace allows surgeons to avoid removing the lymph nodes. It uses a magnetic dye with particles that flow to the sentinel nodes and stays there for 30 days. A pathologist can determine the invasiveness of the cancer by examining removed breast tissue. Then if the cancer is found to be invasive, the surgeon can go back and find the magnetized nodes by listening for the rising pitch of a probe as it closes in on them, much as one would find objects with a metal detector. The technology is pending FDA approval for lumpectomies.

When Breslin faced her double mastectomy in September of 2021 at Allegheny General Hospital, her surgeon told her about Magtrace. “I think I was the first patient of hers that she used it on,” she said.

Advertise with us

In a 2019 study of the technology in Sweden, 78% of 189 women with DCIS undergoing lumpectomy or mastectomy were spared from having a sentinel lymph node biopsy unnecessarily. Additionally, Magtrace successfully enabled delayed lymph node biopsy on the 47 patients whose cancer was found to be invasive.

“As it becomes more well-known and more accepted,” Breslin said, “I think it's going to take a lot of stress off the patient side of things. It's going to decrease the amount of lymphedema that women are going to have after a mastectomy, and I just think that's potentially life changing for a lot of women.”